Last reviewed · How we verify

nicotine acid

GWT-TUD GmbH · Phase 3 active Small molecule

Nicotine acid, also known as niacin, primarily functions by reducing the production of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol in the liver.

Nicotine acid, also known as niacin, primarily functions by reducing the production of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol in the liver. Used for Hypercholesterolemia, Mixed dyslipidemia.

At a glance

Generic namenicotine acid
SponsorGWT-TUD GmbH
Drug classlipid-regulating agent
TargetGPR109A
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

It activates G protein-coupled receptors (GPCRs) such as GPR109A, which can lead to decreased hepatic synthesis of VLDL and increased HDL cholesterol levels, thereby improving lipid profiles.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: